Xel Pharmaceuticals

Xel Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Draper, Utah, dedicated to the development of advanced drug delivery systems, with a primary focus on transdermal and topical patches. Founded in 1999 and formerly known as Xel Herbaceuticals, the company operates as a subsidiary of Orchid Pharma. Xel Pharmaceuticals utilizes its proprietary controlled-release technology to develop innovative treatments for chronic pain, Alzheimer's disease, and urogenital disorders. The company's pipeline features several preclinical small molecule candidates, such as XEL-002BG, which targets voltage-gated sodium channels for pain management. Led by co-founder and Chief Scientific Officer Dr. Danyi Quan, the company aims to improve patient adherence and therapeutic efficacy by providing non-invasive alternatives to oral and injectable medications.